Principal Investigator
Jose Lutzky
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231430
Clinical Trial Summary
A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L)1-refractory Merkel cell carcinoma: The MATRiX Trial
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647